Piper Jaffray analyst Steven Breazzano argues that investors should "take a closer look" at Prothena (PRTA) and its PRX004 product following the recent amyloid neuropathy data from Ionis Pharmaceuticals (IONS). Prothena's candidate is expected to enter the clinic in early 2018, and Breazzano argues that there is "room for differentiation" in the space, as the drug clears the protein buildup that characterizes amyloidosis rather than directly shutting off production, as with Ionis and Alnylam's (ALNY) approaches. "At a minimum," the analyst says, a deposit-clearing approach would be complementary to production-stopping drugs. Breazzano reiterates an Overweight rating on Prothena.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).